Download PREFACE AMENDMENTS TO THE DRUG TARIFF June 2022 and more Summaries Pharmacy in PDF only on Docsity!
i
PREFACE
AMENDMENTS TO THE DRUG TARIFF
June 2022
1. In accordance with regulation 89(3) of the National Health Service (Pharmaceutical and Local Pharma- ceutical Services) Regulations 2013 (“the 2013 Regulations”), the Secretary of State for Health as re- spects England and in accordance with regulation 41(4) of the National Health Service (Pharmaceutical Services) (Wales) Regulations 2013, the Welsh Ministers* as respects Wales have amended the Drug Tariff and determinations made in respect of the amendments to the Drug Tariff shall have effect from 1 August 2015.
For England, by virtue of regulation 91(1) of the 2013 Regulations, the NHS Commissioning Board (“the Board”) has been appointed as a determining authority in relation to the pharmaceutical remuneration listed Schedule 8 to the 2013 Regulations (ie types of service remuneration) and remuneration for advanced services. This means that both the Secretary of State and the Board are able to determine remuneration in these areas, although if the Secretary of State determines remuneration in these areas, he is required to notify the Board of his intention to do so before doing so. As part of a phased transfer of responsibilities between the Secretary of State and the Board, the Board will be acting as the lead determining authority in relation to the following Parts:
- Part IIIA
- Part IIIB
- Part VIA
- Part VIB
- Part VIC (up to Pharmaceutical Services (Advanced and Enhanced Services)(England) Directions
By virtue of Part VIE, the Board is also a determining authority for England for the remuneration for enhanced services and acts as the lead determining authority in that area.
The Secretary of State is the sole determining authority for all other Parts.
Part XI, XIVD, XVIIID and XXI are rescinded in this edition of the Drug Tariff.
Before the Secretary of State, NHS Commissioning Board and the Welsh Ministers make further determinations they will consult with such organisations as appear to be representative of persons to whose remuneration the determination would relate and such other persons as they consider appropriate in respect of determinations which relate to persons providing pharmaceutical services, or a category of such services in accordance with section 165 of the National Health Service Act 2006 and section 89 of the National Health Service (Wales) Act 2006, regulations made under those sections and under section 164 of the National Health Service Act 2006 and section 88 of the National Health Service (Wales) Act 2006.
i) Effective date for all parts except those indicated in (ii) 1st day of the month
ii) Effective date for specific provisions in specified parts N/A
iii) Date of publication 1st day of the month
TO: General Medical Practitioners, Pharmacy Contractors, Appliance Contractors
ii
PREFACE
2. Please note that you are now being supplied each month with the Drug Tariff which incorporates all amendments to date and this will continue until April 2021, when the Drug Tariff will no longer be printed and distributed (please see paragraph 4 for further information regarding these changes to the circulation of the Drug Tariff). All entries showing a change in price are not specifically included in this preface but are indicated in the Drug Tariff by L for price reduction and K for price increase; changes to the text re- lating to code, product description, or the inclusion of a new product are indicated by a vertical line in the margin. 3. While every effort is made to ensure that each monthly publication of the Drug Tariff includes all amendments made by the Secretary of State and the Welsh Ministers to the price applicable to the rele- vant period, the need to observe publishing deadlines sometimes defeats those efforts. Any omitted amendments will be effective from the date on which they came into force, even if publication of the details is unavoidably delayed.
- Functions of the National Assembly for Wales have transferred to Welsh Ministers in accordance with section 162 of and paragraph 30 of Schedule 11 to the Government of Wales Act 2006.
iv
PREFACE
4.2.2 DELETIONS FROM PART IX EFFECTIVE FROM 1 JULY 2022
See Page: 395, 424, 426, 479, 490, 493, 499.
4.3 CHANGES TO JULY 2022 DRUG TARIFF
4.3.1 CHANGES TO PART VIIIA EFFECTIVE FROM 1 JULY 2022
Somatropin (rbe) 10mg powder and solvent for solution for injection vials
1 Category C Zomacton
Somatropin (rmc) 8mg powder and solvent for solution for injection vials
1 Category C Saizen
*Soya oil 84.75% bath oil 1000ml (2xS500ml)
Category C Balneum
Felodipine 10mg modified-release tablets 28 Category C Plendil will be: 28 Category C Cardioplen XL Felodipine 5mg modified-release tablets 28 Category C Plendil will be: 28 Category C Cardioplen XL Sucralfate 1g/5ml oral suspension sugar free 200ml Category C Sigma Pharmaceuticals Ltd will be: 200ml Category A Sulfasalazine 250mg/5ml oral suspension sugar free 500ml Category A will be: 500ml Category C Rosemont Pharmaceuticals Ltd Tamoxifen 10mg/5ml oral solution sugar free 150ml Category A will be: 150ml Category C Rosemont Pharmaceuticals Ltd
v
PREFACE
5. CHANGES TO JUNE 2022 DRUG TARIFF
5.1 PART I - REQUIREMENTS FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REA-
GENTS
Contractors should note changes made to Clause 5 as regards England.
5.2 ADDITIONS TO JUNE 2022 DRUG TARIFF
5.2.1 PART II - REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS
PAGE 31 - DRUGS FOR WHICH DISCOUNT IS NOT DEDUCTED Individual Items Mexiletine 100mg capsules Mexiletine 50mg capsules
PAGE 33 Ogluo solution for injection pre-filled pens (ALL)
PAGE 37 Sucralfate 1g/5ml oral suspension sugar free
5.2.2 PART VIIIA - BASIC PRICES OF DRUGS
PAGE 250
PAGE 293
PAGE 301
PAGE 322
PAGE 354
S Special container
Atorvastatin 20mg/5ml oral suspension sugar free
S 150 ml 19876 C Rosemont Pharmaceuticals Ltd
Fluticasone propionate 100micrograms/dose / Salmeterol 12.75micrograms/ dose dry powder inhaler
S 60 dose 2397 C Seffalair Spiromax
Fluticasone propionate 202micrograms/dose / Salmeterol 12.75micrograms/ dose dry powder inhaler
S 60 dose 2397 C Seffalair Spiromax
Hydrocortisone 15mg tablets 30 2516 A
Hydrocortisone 2.5mg tablets 30 5603 A
Hydrocortisone 5mg tablets 30 1917 A
Metformin 500mg oral powder sachets sugar free
30 630 C Morningside Healthcare Ltd
Sertraline 25mg tablets 28 1450 A
vii
PREFACE
PAGE 512
Eye Ointment - Sodium Chloride
PAGE 516 - HYPODERMIC EQUIPMENT
Needles for Pre-filled and Reusable Pen Injectors pack of 100
PAGE 517
pack of 100
PAGE 610 - PHYSICAL DEBRIDEMENT DEVICE
Physical Debridement Pad
PAGE 611 - PRESSURE OFFLOADING DEVICE
Plantar Pressure Offloading Device
PAGE 612
5.2.4 PART IXB - INCONTINENCE APPLIANCES
PAGE 695 - TUBING AND ACCESSORIES
5.2.5 PART IXC - STOMA APPLIANCES
PAGE 768 - BELTS
SodiEye 6% (5g preservative free tube) 1892
GlucoRx Dual-Safe Pen Needles 5mm/31 gauge 1995
Insupen Original 4mm/33 gauge 249
kliniderm debride 10cm x 14cm 460 kliniderm debride pocket 4cm x 8cm 429
Aircast XP Diabetic Walker System Small 01PD-S 13400 Medium 01PD-M 13400 Large 01PD-L 13400 Pneumatic Walker Diabetic System Extra Large 01PD-XL 13400
Procare IMPAX Diabetic Shoe Insole Small 79-81523 1600 Medium 79-81525 1600 Large 79-81527 1600 Extra Large 79-81528 1600
Off-Loading Diabetic Shoe Small 79-81513 3500 Medium 79-81515 3500 Large 79-81517 3500 Extra Large 79-81518 3500
Argon Medical Devices
Connecting tube for drainage bag one way stopcock/funnel 30cm
Vanilla Blush Vanilla Blush Hernia Support Coresitwell Girdle Ladies Beige X Small-Small (up to 80cm) VBCSWGB1 1 4000 Medium (85cm-95cm) VBCSWGB2 1 4000 Large (95cm-115cm) VBCSWGB3 1 4000 X Large (115cm-135cm) VBCSWGB4 1 4000 XX Large (135cm-148cm) VBCSWGB5 1 4000 XXX Large (148cm-170cm) VBCSWGB6 1 4000
viii
PREFACE
5.3 DELETIONS FROM JUNE 2022 DRUG TARIFF
5.3.1 PART II - REQUIREMENTS ENABLING PAYMENTS TO BE MADE FOR THE SUPPLY OF DRUGS,
APPLIANCES AND CHEMICAL REAGENTS
PAGE 24 - DRUGS FOR WHICH DISCOUNT IS NOT DEDUCTED
Individual Items Co-codaprin 8mg/400mg dispersible tablets
PAGE 35 Polyfusor SB sodium chloride 0.45% infusion 500ml bottles
5.3.2 PART VIIIA - BASIC PRICES OF DRUGS
PAGE 298
PAGE 303
PAGE 313
PAGE 319
Black X Small-Small (up to 80cm) VBCSWG1 1 4000 Medium (85cm-95cm) VBCSWG2 1 4000 Large (95cm-115cm) VBCSWG3 1 4000 X Large (115cm-135cm) VBCSWG4 1 4000 XX Large (135cm-148cm) VBCSWG5 1 4000 XXX Large (148cm-170cm) VBCSWG6 1 4000
Male Black X Small-Small (up to 80cm) VBCSWMG1 1 4000 Medium (85cm-95cm) VBCSWMG2 1 4000 Large (95cm-115cm) VBCSWMG3 1 4000 X Large (115cm-135cm) VBCSWMG4 1 4000 XX Large (135cm-148cm) VBCSWMG5 1 4000 XXX Large (148cm-170cm) VBCSWMG6 1 4000
Grey X Small-Small (up to 80cm) VBCSWMGG1 1 4000 Medium (85cm-95cm) VBCSWMGG2 1 4000 Large (95cm-115cm) VBCSWMGG3 1 4000 X Large (115cm-135cm) VBCSWMGG4 1 4000 XX Large (135cm-148cm) VBCSWMGG5 1 4000 XXX Large (148cm-170cm) VBCSWMGG6 1 4000
S Special container
- This pack only (others still available)
Glycopyrronium bromide powder for solution for iontophoresis
3 g 32700 C Advanz Pharma
Hypromellose 0.3% eye drops S 10 ml 105 C Martindale Pharmaceuticals Ltd
- Levofloxacin 250mg tablets 5 396 A
Maraviroc 25mg tablets 120 14709 C Celsentri
Maraviroc 75mg tablets 120 44127 C Celsentri
x
PREFACE
5.4 OTHER CHANGES TO JUNE 2022 DRUG TARIFF
5.4.1 PART VIIIA - BASIC PRICES OF DRUGS
PAGE 258
Now Reads
PAGE 260
Now Reads
PAGE 268
Now Reads
PAGE 275
Now Reads
PAGE 292
Now Reads
PAGE 301
Now Reads
S Special container
Calcipotriol 0.005% / Betamethasone dipropionate 0.05% gel
S 60 g 3721 C Dovobet
Calcipotriol 0.005% / Betamethasone dipropionate 0.05% gel
S 60 g 3628 A
Carbocisteine 750mg/5ml oral solution sugar free
200 ml 2182 C Lucis Pharma Ltd
Carbocisteine 750mg/5ml oral solution sugar free
200 ml 2449 A
Co-codamol 15mg/500mg capsules
100 1071 A
Co-codamol 15mg/500mg capsules
100 725 C Codipar
Dexamethasone 20mg/5ml oral solution sugar free
50 ml 4950 C Advanz Pharma
Dexamethasone 20mg/5ml oral solution sugar free
50 ml 4200 C Synchrony Pharma Ltd
Fluoxetine 30mg capsules 30 180 C Medreich Plc
Fluoxetine 30mg capsules 30 217 A
Hydrocortisone 2.5% ointment S 15 g 2446 A
Hydrocortisone 2.5% ointment S 15 g 4400 C Essential Generics Ltd
xi
PREFACE
PAGE 319
Now Reads
PAGE 334
Now Reads
PAGE 363
Now Reads
Now Reads
Now Reads
PAGE 364
Now Reads
Now Reads
Mebeverine 50mg/5ml oral suspension sugar free
300 ml 18700 A
Mebeverine 50mg/5ml oral suspension sugar free
300 ml 18700 C Essential Generics Ltd
Oily phenol 5% solution for injection 5ml ampoules
10 9380 A
Oily phenol 5% solution for injection 5ml ampoules
10 9380 C Martindale Pharmaceuticals Ltd
Tapentadol 100mg modified- release tablets
56 4982 C
Tapentadol 100mg modified- release tablets
56 4982 C Palexia SR
Tapentadol 150mg modified- release tablets
56 7473 C
Tapentadol 150mg modified- release tablets
56 7473 C Palexia SR
Tapentadol 200mg modified- release tablets
56 9964 C
Tapentadol 200mg modified- release tablets
56 9964 C Palexia SR
Tapentadol 250mg modified- release tablets
56 12455 C
Tapentadol 250mg modified- release tablets
56 12455 C Palexia SR
Tapentadol 50mg modified-release tablets
56 2491 C
Tapentadol 50mg modified-release tablets
56 2491 C Palexia SR
xiii
PREFACE
5.4.4 PART IXC - STOMA APPLIANCES
PAGE 973 - UROSTOMY BAGS
Now Reads
Now Reads
5.4.5 PART IXR - CHEMICAL REAGENTS
PAGE 989
Now Reads
5.4.6 Part XV - Borderline Substances
PAGE 1017 - LIST A
Aymes ActaGain Juce (Apple, Orange, Mango & Passionfruit and Raspberry Flavours) (formerly Aymes ActaJuce (Apple and Orange Flavours)) For the dietary management of short-bowel syndrome, intractable malabsorption, pre-operative preparation of undernourished patients, inflammatory bowel disease, total gastrectomy, bowel fistulae and disease- related malnutrition. Now Reads
Aymes ActaGain Juce (Apple, Cranberry & Raspberry, Mango & Passionfruit and Orange Flavours) (formerly Aymes ActaJuce (Apple and Orange Flavours)) For the dietary management of short-bowel syndrome, intractable malabsorption, pre-operative preparation of undernourished patients, inflammatory bowel disease, total gastrectomy, bowel fistulae and disease- related malnutrition.
Q These product codes will change in the June 2022 Drug Tariff
Oakmed Ltd Option Urostomy Clear with soft covering to one side Clear Q cut-to-fit 13-60mm GC1300C 20 9699
Option Urostomy Clear with soft covering to one side Clear cut-to-fit 15-60mm GC1500C 20 9699
Option Urostomy with soft covering to both sides with window Q cut-to-fit 13-50mm GC1300 20 9869
Option Urostomy with soft covering to both sides with window cut-to-fit 15-50mm GC1500 20 9869
X to be deleted 1 June 2022
XDetection Pad, Sweat for Neuropathy Neuropad 2 728
Detection Pad, Sweat for Neuropathy Neuropad 2 728
xiv
PREFACE
This Page is Intentionally Blank
CONTENTS
Part XVIIIC Criteria notified under the Transparency Directive ............................................. 1153
Part XVIIID The National Health Service Litigation Authority (Pharmaceutical Remuneration - Pay-
ment Disputes) (England) Directions 2022 ........................................................ 1154
Part XIX Payments to Chemists Suspended by the NHS Commissioning Board or by Direction
of the First-Tier Tribunal ..................................................................................... 1158
Part XX Requisitions and Private Prescriptions for Controlled Drugs.............................. 1163
Part XXI Rescinded - Intentionally Blank .......................................................................... 1165
06/2022 Definitions
Definitions -
DEFINITIONS
(a) Except where the context otherwise requires, the terms to which a meaning is assigned by the Regulations or the Terms of Service have the same meaning in this Tariff.
(b) The term ‘contractor’ has for Wales the same meaning as ‘chemist’ as defined in the National Health Service (Pharmaceutical Services) Regulations 1992 and for England the same meaning as ‘NHS chemist’ as defined in the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations
- LPS chemists will also need to be paid at least part of their remuneration (depending on the terms of their scheme) in accordance with the Drug Tariff, and so at least some references to ‘contractor’ will apply equally to them.
(c) A pharmacy contractor is a person with whom the NHS Commissioning Board (NHSCB) for England and Local Health Board (LHB) for Wales has made arrangements for the provision of pharmaceutical services in respect of the supply of drugs, appliances and chemical reagents.
(d) An appliance contractor is a person with whom the NHSCB for England and LHB for Wales has made arrangements for the provision of pharmaceutical services so far as it relates to the supply of appliances included within Part IXA/B/C of this Tariff.
(e) The term persons includes a body of persons corporate or unincorporate.
(f) The term Pricing Authority means, as the case may require, the NHS Business Services Authority (NHSBSA) or the NHS Wales Shared Services Partnership (NWSSP).
(g) The term appliances as used in this Tariff includes dressings.
(h) The term prescription refers to an item on a prescription form or dispensed in accordance with a repeatable prescription.
(i) The term prescription form includes, where appropriate, a repeatable prescription.
(j) The term pharmacy means any premises where drugs are provided by a pharmacist or pharmacy business as part of pharmaceutical services under section 126 (arrangements for pharmaceutical services) for England of the National Health Service Act 2006 and Section 80 of the National Health Service (Wales) Act
(k) Specials are unlicensed medicinal products manufactured in the UK for human use which have been specially prepared to meet a prescription ordered for individual patients without the need for the manufacturer to hold a marketing authorisation for the medicinal product concerned.
(l) Imported products are unlicensed medicinal products sourced from outside the UK under an importers licence issued by the MHRA. These products have been specially sourced to meet a prescription ordered for individual patients without the need for the importer to hold a marketing authorisation for the medicinal product concerned.
In the preparation of this Tariff the Secretary of State for Health and the Welsh Ministers have consulted the Pharmaceutical Services Negotiating Committee.
06/2022 Part I
REQUIREMENTS FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS
(c) destroy any batch issues relating to drugs, appliances or chemical reagents which are not required, or which should not be dispensed because the contractor has been notified to that effect by the doctor who issued them or because the relevant repeatable prescription has expired; and (d) populate the appropriate claim form on the Manage Your Service (MYS) platform to reflect repeat dispensing services and submit it by no later than the 5th day of the following month in which the supply was made 2. Contractors must also print the populated FP34C form from the MYS platform and submit it alongside paper prescriptions as per Clause 5A 1 and 2.
- Prescriptions via the Electronic Prescription Service - contractors must:
(a) ensure that the Electronic Reimbursement Endorsement Messages (EREMs)^3 include the endorsement requirements as required by Clause 9, Part II, ans submit the EREMs via EPS to NHS Prescription Services for England for receipt at the Pricing Authority by no later than the 5th day of the month following that in which the supply was made 4. Contractors should note that any EREMs sent after the 5th of the following month in which supply was made will be priced with next month’s claim. EREMs sent later than 180 days after the Dispense Notification was sent, will not be subject to payment; and (b) annotate the number of submitted EREMs on the appropriate claim form on the Manage Your Service (MYS) platform as per Clause 5A 1 and 2^5 ; and (c) all EPS tokens must be:
(i) sorted separately from FP10 paper prescription forms with the exception of age exempt and any other tokens specified on the FP34C which must not be submitted (unless there is an exemption under Part XVI;) and (ii) dispatched in the same parcel as per Clause 5A 1 and 2.
Contractors should note that EPS tokens may be checked against claims for payment for audit purposes and possible enforcement action. The legal position is that payment will be made against the EREM, not the EPS token, and so prescription charges will be deducted, even if there is a failure to properly record an exemption that the patient can properly claim in the EREM, and if the EPS token correctly records this, unless contractors request a recheck under Part XIVB.
It is a condition of entitlement to exemption from prescription charges that the patient or their representative claiming exemption must make and duly complete a declaration of entitlement unless an automatic exemption applies 6. Where applicable, the contractor must ensure that the patient declaration is recorded on the system.
In the case of automatic exemptions 6 , electronic prescriptions and paper prescriptions are similar, in that regardless of the exemption or charge information populated either by the patient/representative or the contractor, it will be disregarded (i.e. even if there is an error on the EREM, or the paper prescription states that a prescription charge was taken or if it is on a prescription with an additional chargeable item, the charge will not be deducted).
(^3) Pharmacy contractors should note that the Dispense Notification must be sent before the EREM.
(^4) Pharmacy contractors are encouraged to submit EREMs throughout the month.
(^5) Where one or more bank holiday occurs within the first five days of the month, dispatch must be secured by the
6th of that month. Note: The requirement to submit EREMs within the first 5 days remains unchanged. Note: For May 2022 prescriptions, contractors must secure dispatch by 7 June 2022.
(^6) This includes age exempt prescriptions, prescription forms with only free-of-charge sexual health medication
and/or contraceptives, where Real Time Exemption Checking (RTEC) confirms an exemption and where a smaller quantity (in comparison with the prescription) of a drug is supplied in accordance with an SSP.
- Claims in exceptional circumstances preventing the contractor from submitting the FP34C form as outlined in Clause 5A 1, 2 and 3. (a) In exceptional circumstances, where the contractor through no fault of their own, is unable to submit the FP34C form through the MYS portal, contractors are advised to contact the NHSBSA either through email nhsbsa.mys@nhs.net or by contacting the MYS helpdesk number (0300 330 1368). Contractors should note that this route is available only for emergencies, which are directly related to the contractor (for example internet outage in the contractor’s area) and not related to the MYS platform itself (in case of the MYS platform being down there will be instructions for contractors on the NHSBSA’s website on what to do);
06/2022 Part I
REQUIREMENTS FOR THE SUPPLY OF DRUGS, APPLIANCES AND CHEMICAL REAGENTS
(b) Contractors, who will be using the email route, are advised that they must apply an advanced electronic signature to the email to secure payment; and
(c) Contractors, who will be using the telephone route, are advised that the NHSBSA will contact the contractor via a preferred email address for the contractor, which the contractor has shared with them during the phone call conversation, for them to confirm that the claim the NHSBSA noted via the phone call was correct, and the contractor must apply an advanced electronic signature to the confirmation email to secure payment.
Claims for payment for Wales
- Paper prescriptions - contractors must:
(a) Endorse prescription forms 7 as required in Clause 9 (Endorsement Requirements) of this Tariff; and
(b) Dispatch the prescription forms to the relevant division of the Primary Care Services (PCS): (i) with the appropriate claim form; (ii) sorted 8 as appropriate; (iii) in a secure manner that enables tracking and tracing of the delivery; and (iv) for receipt by no later than the 8th working day of the month following that in which the supply was made.
- Repeat dispensing services - contractors must:
(a) endorse batch issues as required in Clause 9 (Endorsement Requirements) of this Tariff. In addition, batch issues relating to drugs, appliances or chemical reagents which have been dispensed must be stamped with the contractor's stamp and dated with the date on which the items were dispensed.
(b) dispatch the batch issues (in the same parcel as per Clause 5A 5) relating to drugs, appliances or chemical reagents which have been dispensed to the PCS: (i) with the appropriate claim form; (i) sorted 8 as appropriate; (ii) in a secure manner that enables tracking and tracing of the delivery; and (iii) for receipt by no later than the 8th working day of the month following that in which the supply was made. (c) destroy any batch issues relating to drugs, appliances or chemical reagents which are not required, or which should not be dispensed because the contractor has been notified to that effect by the doctor who issued them or because the relevant repeatable prescription has expired; and
(d) retain repeatable prescriptions until they have expired or are no longer required and then dispatch them to the PCS for Wales: (i) sorted 8 as appropriate separate from the batch issues; (ii) in a secure manner that enables tracking and tracing of the delivery; and (iii) in the month following that in which they expired, or the contractor became aware that they were no longer required.
(^7) For the purpose of Part I of the Drug Tariff, wherever prescriptions, prescription forms or batch issues are
mentioned, this includes prescription forms where supply was made in accordance with a Serious Shortage protocol (SSP).
(^8) Minimum Standard for Submission of Monthly Account.
- To ensure the accurate and timely payment of accounts each month prescriptions must meet minimum submission standards. Details of minimum submission standards can be found on the Shared Services Partnership website.
- Contractors are responsible for training staff involved in the preparation of prescriptions for transit and submission. Further supporting information and training material can be found on the Shared Services Partnership website.
Failure to submit accounts in a timely manner may result in advance payments not being processed. In addition, accounts that fail to meet the minimum standards set out at 1 above may be subject to financial penalty.
